Recent Healthcare Financings
| Company Name | Amount Raised | Type of Fundraise | Country | Date |
| Private Company Financings | ||||
| Azalea Therapeutics | $82 million | Combined seed & Series A | US | 4 November |
| NEOK Bio | $75 million | Series A | US | 4 November |
| Braveheart Bio | $185 million | Series A | US | 5 November |
| Onchilles Pharma | $25 million | Series A | US | 7 November |
| Modulight Biotherapeutics | $12 million | Seed | US | 12 November |
| Gate Bioscience | $65 million | Series B | US | 13 November |
| Artios | $115 million | Series D | UK | 17 November |
| Solve Therapeutics | $120 million | N/A | US | 17 November |
| AI Proteins | $41.5 million | Series A | US | 18 November |
| Thrivory | £3.5 million | Seed | US | 18 November |
| Lifordi Immunotherapeutics | $42 million | N/A | US | 18 November |
| Profluent | $106 million | N/A | US | 19 November |
| Function Health | $298 million | Series B | US | 19 November |
| Aspen Neuroscience | $115 million | Series C | US | 20 November |
| Dayra Therapeutics | $70 million | N/A | Canada | 24 November |
| Public Company Financings | ||||
| Relmada Therapeutics, Inc | $100 million | Public Offering | US | 4 November |
| MoonLake Immunotherapeutics AG | $75 million | Public Offering | Switzerland | 5 November |
| 4D Molecular Therapeutics, Inc. | $100 million | Public Offering | US | 6 November |
| Opus Genetics | $100 million | Public Offering | US | 6 November |
| Vor Bio | $100 million | Public Offering | US | 10 November |
| Iambic Therapeutics | $100 million | Public Offering | US | 10 November |
| Cogent Biosciences | $475.3 million | Public Offering | US | 11 November |
| Annexon | $86.3 million | Public Offering | US | 14 November |
[JE1]Have added Trogenix – announced 6 October – https://trogenix.com/trogenix-announces-95-million-series-a-financing/